UnitedHealthcare to let consumers share in rebates from drugmakers

UnitedHealthcare announced a plan to provide patients drug rebates starting in 2019. (Pixabay)

Amid a clash between pharma and payers over high U.S. drug prices, leading payer UnitedHealthcare is planning to offer rebates directly back to millions of patients—a move that addresses a top criticism from the drug industry. 

UnitedHealthcare plans to offer more than 7 million fully insured members negotiated discounts starting on January 1, 2019, allowing them to save anywhere from "a few dollars" to more than $1,000 per year, CEO Dan Schumacher told the New York Times. 

As drugmakers have taken heat over high drug prices, they have tried to deflect criticism by pointing to rebating strategies at PBMs as the culprit. Pharma has said patients don't benefit from tough behind-the-scenes negotiations that drive down prices, and that it's sometimes unclear where the rebates go. UnitedHealthcare's parent group owns the PBM OptumRx.

On-Demand Webinar

De-Risking the Solid Form Landscape of an API

This presentation will discuss how predictable stability and solubility can minimize development timelines and cost. Attend to hear about two case studies exemplifying the importance of understanding the hydration space of an API and how hydrate formation may be avoided by development of a robust crystallization procedure.

Eli Lilly CEO David Ricks recently suggested direct-to-customer rebates as one idea to fight high U.S. drug prices, along with value-based pricing. 

In turn, PBMs have said their negotiations save the healthcare system billions of dollars and that drug companies always set their own prices.  

RELATED: PBMs counter pharma's pricing blame with proposals to cut $100B in drug costs 

UnitedHealthcare said rebates already provide cost relief to the entire healthcare system, but the new approach will provide individual customers savings.

Not all drugs come with rebates, according to the Times. Members can see the price of their drug—including the rebate amount—before going to the pharmacy or placing a delivery order, according to a release.

RELATED: Drug discounting to insurers soars from 28% to 41% in 5 years, with no end in sight: report 

Rebating has been a contentious topic in the drug industry for years, and the Trump Administration recently suggested shakeups to Medicare Part D to allow beneficiaries to access rebates paid out by drugmakers. PCMA, the organization that represents pharmacy benefit managers, said the proposal "runs contrary to the Administration’s goal to reduce drug costs." 

The group said the change would increase premiums for all seniors and only benefit a subset of patients on certain medications.

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.